Regeneron is already working on ramping ... It is being tested in phase 2/3 trials both as a treatment for coronavirus infections as well as prophylaxis against infection in people exposed to ...

as well as antibodies isolated from humans who had recovered from COVID-19. Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up ...

In a small study, patients with the syndrome were more likely to experience reactivation of Epstein-Barr virus and high ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Regeneron settles patent lawsuit over protein for testing COVID-19 treatments December 16, 2024 AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed ...

A study on bat genomes, involving Texas Tech University, discovered genetic adaptations that help bats resist viral ...

Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

Regeneron Pharmaceuticals announced positive ... of EYLEA HD's effectiveness and support its potential to reduce treatment burdens for elderly patients. At three years of treatment with EYLEA ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN ... the known safety profile of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in greater than or ...